2000 Participants Needed

COVID-19 for Kidney Injury

(KIDCOV Trial)

Recruiting at 4 trial locations
TM
TS
JC
MS
TS
Overseen ByTara Sigdel, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, San Francisco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand how mild or symptom-free COVID-19 affects kidney health over time. Researchers will collect urine samples from individuals who have tested both positive and negative for COVID-19 to determine if the virus impacts kidney function differently. Participants can mail their samples to the study team at set intervals without leaving home. Individuals who have tested for COVID-19 within the last four weeks and have not been hospitalized or undergone a kidney transplant are suitable for this study. As an unphased study, this trial allows participants to contribute to important research that could enhance understanding of COVID-19's long-term effects on kidney health.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your medications, but it's best to confirm with the study team.

Why are researchers excited about this trial?

Researchers are excited about the KIDCOV trial because it focuses on understanding how COVID-19 affects kidney health, particularly acute kidney injury (AKI). Unlike traditional treatments that aim to alleviate kidney injury through medications or dialysis, this trial uses urine collection to study the progression and risk factors associated with kidney damage in both COVID-19 positive and negative patients. By comparing these groups, researchers hope to uncover key insights into how COVID-19 might uniquely impact kidney function, potentially leading to more targeted and effective treatments in the future.

Who Is on the Research Team?

MS

Minnie Sarwal, M.D., Ph.D.

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

Inclusion Criteria

Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC
Race/ethnicity, sex, age, and phone and/or home/email address provided

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Baseline Assessment

Participants complete online consent and initial questionnaires, and receive urine collection kits

1 week

Follow-up

Participants are monitored for kidney injury through urine samples collected at 2, 6, and 12 months

12 months
3 sample collections (mail-in)

What Are the Treatments Tested in This Trial?

Interventions

  • Urine Collection
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: COVID-19 PositiveExperimental Treatment1 Intervention
Group II: COVID-19 NegativeExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials
2,636
Recruited
19,080,000+

Rush University Medical Center

Collaborator

Trials
448
Recruited
247,000+

University of Michigan

Collaborator

Trials
1,891
Recruited
6,458,000+

University of California

Collaborator

Trials
46
Recruited
208,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security